Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03440424
Recruitment Status : Completed
First Posted : February 21, 2018
Last Update Posted : September 6, 2018
Sponsor:
Collaborator:
Purdue Pharma LP
Information provided by (Responsible Party):
Eisai Inc.

Brief Summary:
This study will be conducted to assess the effect of mild and moderate hepatic impairment on the pharmacokinetics (PK) of lemborexant after a single-dose administration.

Condition or disease Intervention/treatment Phase
Hepatic Impairment Drug: Lemborexant Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Parallel-Group Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects
Actual Study Start Date : January 26, 2018
Actual Primary Completion Date : April 23, 2018
Actual Study Completion Date : April 23, 2018

Arm Intervention/treatment
Experimental: Cohort A: Mild Hepatic Impairment (Child Pugh Class A)
Participants with mild hepatic impairment will receive a single 10 milligram (mg) dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 milliliters (mL) of water following an overnight fast of at least 10 hours.
Drug: Lemborexant
oral tablet

Experimental: Cohort B: Moderate Hepatic Impairment (Child Pugh Class B)
Participants with moderate hepatic impairment will receive a single 10 mg dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 mL of water following an overnight fast of at least 10 hours.
Drug: Lemborexant
oral tablet

Experimental: Cohort C: Healthy Participants (Control)
Healthy participants matched to participants in Cohorts A and B will receive a single 10 mg dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 mL of water following an overnight fast of at least 10 hours.
Drug: Lemborexant
oral tablet




Primary Outcome Measures :
  1. Mean maximum plasma concentration (Cmax) of lemborexant [ Time Frame: Blood samples will be obtained at predose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 (Day 1); 24 (Day 2); 48 (Day 3); 72 (Day 4); 96 (Day 5); 120 (Day 6); 144 (Day 7); 168 (Day 8); 216 (Day 10); 264 (Day 12); and 312 (Day 14) hours postdose. ]
  2. Mean area under plasma concentration versus time curve from time = 0 to time of last quantifiable concentration (AUC [0-t]) of lemborexant [ Time Frame: Blood samples will be obtained at predose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 (Day 1); 24 (Day 2); 48 (Day 3); 72 (Day 4); 96 (Day 5); 120 (Day 6); 144 (Day 7); 168 (Day 8); 216 (Day 10); 264 (Day 12); and 312 (Day 14) hours postdose. ]
  3. Mean area under plasma concentration versus time curve from time = 0 to infinity (AUC[0-inf]) of lemborexant [ Time Frame: Blood samples will be obtained at predose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 (Day 1); 24 (Day 2); 48 (Day 3); 72 (Day 4); 96 (Day 5); 120 (Day 6); 144 (Day 7); 168 (Day 8); 216 (Day 10); 264 (Day 12); and 312 (Day 14) hours postdose. ]

Secondary Outcome Measures :
  1. Mean time to reach maximum plasma concentration (Tmax) of lemborexant and its metabolites [ Time Frame: Blood samples will be obtained at predose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 (Day 1); 24 (Day 2); 48 (Day 3); 72 (Day 4); 96 (Day 5); 120 (Day 6); 144 (Day 7); 168 (Day 8); 216 (Day 10); 264 (Day 12); and 312 (Day 14) hours postdose. ]
  2. Mean terminal plasma phase half-life (t½) of lemborexant and its metabolites [ Time Frame: Blood samples will be obtained at predose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 (Day 1); 24 (Day 2); 48 (Day 3); 72 (Day 4); 96 (Day 5); 120 (Day 6); 144 (Day 7); 168 (Day 8); 216 (Day 10); 264 (Day 12); and 312 (Day 14) hours postdose. ]
  3. Mean apparent total body clearance (CL/F) of lemborexant [ Time Frame: Blood samples will be obtained at predose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 (Day 1); 24 (Day 2); 48 (Day 3); 72 (Day 4); 96 (Day 5); 120 (Day 6); 144 (Day 7); 168 (Day 8); 216 (Day 10); 264 (Day 12); and 312 (Day 14) hours postdose. ]
  4. Mean apparent volume of distribution (Vz/F) of lemborexant [ Time Frame: Blood samples will be obtained at predose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 (Day 1); 24 (Day 2); 48 (Day 3); 72 (Day 4); 96 (Day 5); 120 (Day 6); 144 (Day 7); 168 (Day 8); 216 (Day 10); 264 (Day 12); and 312 (Day 14) hours postdose. ]
  5. AUC Metabolite Ratio [ Time Frame: Blood samples will be obtained at predose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 (Day 1); 24 (Day 2); 48 (Day 3); 72 (Day 4); 96 (Day 5); 120 (Day 6); 144 (Day 7); 168 (Day 8); 216 (Day 10); 264 (Day 12); and 312 (Day 14) hours postdose. ]
    The AUC metabolite ratio is the ratio of AUC(0-inf) of the individual metabolite to AUC(0-inf) of lemborexant, corrected for molecular weights.

  6. Plasma protein unbound fraction (fu) of lemborexant and its metabolites [ Time Frame: Blood samples will be obtained at 1 and 24 hours postdose. ]
  7. Mean AUC(0-inf) values adjusted by unbound fraction in plasma (AUCu) of lemborexant [ Time Frame: Blood samples will be obtained at predose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 (Day 1); 24 (Day 2); 48 (Day 3); 72 (Day 4); 96 (Day 5); 120 (Day 6); 144 (Day 7); 168 (Day 8); 216 (Day 10); 264 (Day 12); and 312 (Day 14) hours postdose. ]
  8. Mean apparent clearance relative to the unbound plasma concentration based on AUCu (CLu/F) of lemborexant [ Time Frame: Blood samples will be obtained at predose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 (Day 1); 24 (Day 2); 48 (Day 3); 72 (Day 4); 96 (Day 5); 120 (Day 6); 144 (Day 7); 168 (Day 8); 216 (Day 10); 264 (Day 12); and 312 (Day 14) hours postdose. ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Inclusion Criteria for All Participants:

  • Male or female participants, ages 18 to 79, inclusive, at the time of informed consent
  • Body Mass Index (BMI) between 18 and 40 kilograms per meters squared, inclusive, at Screening
  • Voluntary agreement to provide written informed consent, and the willingness and ability to comply with all aspects of the protocol
  • Nonsmokers or smokers who smoke 20 cigarettes or less per day
  • For Cohorts A and B: stable (without any change in disease status for at least 60 days prior to study Screening) hepatic impairment conforming to Child-Pugh classification A or B, respectively, and documented by medical history and a physical examination
  • For Cohort C: healthy participants matched to participants with hepatic impairment with regard to age (±10 years), sex, and BMI (±20%), and as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiogram (ECG), and clinical laboratory determinations

Exclusion Criteria:

Exclusion Criteria for All Participants:

  • Females who are breastfeeding or pregnant at Screening or Baseline
  • Females of childbearing potential. Note: All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (i.e., bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing).
  • Known to be positive for human immunodeficiency virus
  • Currently enrolled in another clinical study or used any investigational drug or device within 4 weeks, or 5 times the half-life of the investigational drug (whichever is longer), preceding informed consent
  • Receipt of blood products within 4 weeks, or donation of blood within 8 weeks, or donation of plasma within 1 week of dosing until study discharge
  • Intake of herbal preparations containing St. John's Wort within 4 weeks prior to dosing until study discharge
  • Intake of nutritional supplements (including herbal preparations), foods or beverages that may affect cytochrome P3A enzyme (e.g., alcohol, grapefruit, grapefruit juice, grapefruit-containing beverages, apple or orange juice, vegetables from the mustard green family [e.g., kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard] and charbroiled meats) within 1 week before dosing until study discharge
  • Intake of beverages, food, or other products that contain caffeine from 24 hours before until 48 hours after dosing with lemborexant
  • Engagement in strenuous exercise (e.g., moving large bulky items, bodybuilding) within 2 weeks prior to check-in until study discharge
  • History of clinically significant drug or food allergies, or is presently experiencing significant seasonal allergies
  • A prolonged QT/corrected QT (QTc) interval (QTc >480 milliseconds) demonstrated on ECG at Screening or Baseline (Day -1)
  • Any major surgery within 4 weeks of study drug administration
  • Any history of abdominal surgery that may affect pharmacokinetics of lemborexant (e.g., hepatectomy, nephrectomy, digestive organ resection)
  • Inability to tolerate oral medication
  • Inability to tolerate venous access and/or venipuncture
  • Unwilling to abide by the study requirements, or in the opinion of the investigator, is not likely to complete the study

Additional Exclusion Criteria for Hepatically Impaired Participants (Cohorts A and B):

In addition to the Exclusion Criteria listed above for all participants, other standard exclusion criteria for participants with hepatic impairment will be used. These include:

  • Any significant acute medical illness (such as new conditions or exacerbation of pre-existing conditions) within 8 weeks of dosing
  • Medical conditions which are not adequately and stably controlled on stable doses of medications or which, in the clinical opinion of the Principal Investigator, may interfere with study procedures or participant safety within 4 weeks before dosing (e.g., psychiatric disorders and disorders of the gastrointestinal tract, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system, or participants who have a congenital abnormality in metabolism)
  • History of esophageal and gastric variceal bleeding within the past 6 months unless the participant has completed a course of endoscopic therapy with the appropriate documentation (e.g., endoscopy report) of successful ablation of esophageal varices; participants with esophageal varices may be included if not bleeding within the past 6 months or have been treated adequately by ablation therapy, as specified above.
  • Spontaneous bacterial peritonitis within 3 months of dosing
  • Treatment with plasmapheresis within 6 months of dosing
  • Primarily cholestatic liver diseases (e.g., primary biliary cirrhosis or primary sclerosing cholangitis)
  • Current or recent (within 3 months prior to Screening) history of significant gastrointestinal disease other than that secondary to hepatic impairment
  • Autoimmune liver disease
  • Active alcoholic hepatitis determined either clinically or by histology
  • History of hepatoma or metastatic disease of the liver
  • Presence of severe ascites or edema
  • Presence of hepatopulmonary syndrome or hydrothorax, or hepatorenal syndrome
  • Known significant bleeding diathesis that could preclude multiple venipunctures (international normalization ratio >2.5)
  • Creatinine clearance <60 milliliters per minute at Screening or Baseline as calculated using Cockroft and Gault Equation
  • The participant's standard therapy/concomitant medication for diseases related to cirrhosis has not remained stable/unchanged for at least 14 days before the first dose of study drug
  • History of drug or alcohol dependency or abuse within 4 weeks prior to Screening, or those who have a positive urine drug test or breath alcohol test at Screening or Baseline unless a prescribed medication for the underlying condition is the cause of the positive urine screen

Additional Exclusion Criteria for Healthy Participants (Cohort C):

In addition to the Exclusion Criteria listed above for all participants, other standard exclusion criteria for healthy participants in Phase 1 studies will be used. These include:

  • Presence of active liver disease, or acute liver injury, as indicated by (1) an abnormal liver function test, or (2) clinical or laboratory signs of active viral hepatitis (including B and C, as demonstrated by positive serology at Screening)
  • Clinically significant illness, within 4 weeks prior to dosing, that requires medical treatment or may influence the outcome of the study; e.g., psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system, or participants who have a congenital abnormality in metabolism
  • Any abnormal finding based on physical examination, assessment of vital signs, ECG, or laboratory test results that require treatment or clinical follow-up based on the investigator's opinion
  • History of drug or alcohol use disorder within the 2 years prior to Screening, or those who have a positive urine drug test or breathalyzer alcohol test at Screening or Baseline
  • Use of any prescription drugs within 4 weeks prior to dosing until study discharge
  • Intake of any over-the-counter medications within 2 weeks prior to dosing until study discharge

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03440424


Locations
Layout table for location information
United States, Florida
Clinical Pharmacology of Miami, LLC
Miami, Florida, United States, 33014
Orlando Clinical Research Center
Orlando, Florida, United States, 32809
Sponsors and Collaborators
Eisai Inc.
Purdue Pharma LP

Layout table for additonal information
Responsible Party: Eisai Inc.
ClinicalTrials.gov Identifier: NCT03440424     History of Changes
Other Study ID Numbers: E2006-A001-104
First Posted: February 21, 2018    Key Record Dates
Last Update Posted: September 6, 2018
Last Verified: February 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Eisai Inc.:
mild hepatic impairment
moderate hepatic impairment
lemborexant
healthy participants
metabolites
E2006
pharmacokinetics

Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
Digestive System Diseases